Latest Updates on Lipid Management

  • Emmanuel Eroume-A. EgomEmail author
  • Rebabonye B. Pharithi
  • Soressa Hesse
  • Neasa Starr
  • Richard Armstrong
  • Habitha Mohammed Sulaiman
  • Katarina GazdikovaEmail author
  • Ioana Mozos
  • Martin Caprnda
  • Peter Kubatka
  • Peter KruzliakEmail author
  • Barkat Khan
  • Ludovit GasparEmail author
  • Vincent M. G. MaherEmail author
Review article


Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. Despite the clinical long-term and near-term benefits of lowering cholesterol in, respectively, primary and secondary prevention of ASCVD, cholesterol levels remain under-treated, with many patients not achieving their recommended targets. The present article will review the latest updates on lipid management with emphases on the different classes of cholesterol-lowering agents and their clinical uses.


ASCVD Atherosclerotic cardiovascular disease Cholesterol Lipid management Triglycerides 


Compliance with Ethical Standards

Conflicts of interest

Authors declare no conflict of interest.

Research involving human participants and/or animals

Not applicated, this is review paper.

Informed consent

Not applicated, this is review paper.


  1. 1.
    De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1–10.PubMedGoogle Scholar
  2. 2.
    WHO. Cardiovascular diseases (CVDs). WHO 2017. Accessed 16 Aug 2017.
  3. 3.
    Alonge VO, Grant T, Drummond A, Sugrue D, Codd M. Cardiovascular disease burden in acute public hospitals in Ireland: estimates for 2021 and 2031. Ir J Med Sci. 2013;182:245–53.CrossRefPubMedGoogle Scholar
  4. 4.
    Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.CrossRefPubMedGoogle Scholar
  5. 5.
    Anderson KM, Castelli WP, Levcy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Goldbourt U, Yaari S. Cholesterol and coronary heart disease mortality. A 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990;10:512–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Karalis DG, Victor B, Ahedor L, Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol. 2012;2012:1–7.CrossRefGoogle Scholar
  8. 8.
    Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.CrossRefPubMedGoogle Scholar
  9. 9.
    Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511.CrossRefPubMedGoogle Scholar
  10. 10.
    McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, INTERHEART Study Investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet. 2008;372:224–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Reiner Z. How to improve cardiovascular diseases prevention in Europe? Nutr Metab Cardiovasc Dis. 2009;19:451–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Rabar S, Harker M, O’Flynn N, Wierzbicki AS, Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:g4356.CrossRefPubMedGoogle Scholar
  14. 14.
    Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569–78.CrossRefPubMedGoogle Scholar
  15. 15.
    Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009;169:659.CrossRefPubMedGoogle Scholar
  16. 16.
    Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Medical; 2011. p. 634–89.Google Scholar
  17. 17.
    Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13:278–88.CrossRefPubMedGoogle Scholar
  18. 18.
    Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63:S5–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30–42.CrossRefPubMedGoogle Scholar
  21. 21.
    Keys A. Serum cholesterol response to dietary cholesterol. Am J Clin Nutr. 1984;40:351–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Abumweis SS, Barake R, Jones PJH. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008. Scholar
  23. 23.
    Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Sirtori CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis. 2009;203:8–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Shaw KA, Gennat HC, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev. 2006. Scholar
  26. 26.
    Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM, Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia. JAMA. 2006;295:2262.CrossRefPubMedGoogle Scholar
  29. 29.
    Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Bantle JP, Raatz SK, Thomas W, Georgopoulos A. Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr. 2000;72:1128–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322–34.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483–92.CrossRefPubMedGoogle Scholar
  33. 33.
    Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors. Arch Intern Med. 2006;166:285.CrossRefPubMedGoogle Scholar
  34. 34.
    Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–54S.CrossRefPubMedGoogle Scholar
  35. 35.
    Beulens JWJ, Rimm EB, Ascherio A, Spiegelman D, Hendriks HFJ, Mukamal KJ. Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Intern Med. 2007;146:10–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Rabkin SW. Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis: a control clinical trial. Atherosclerosis. 1984;53:173–84.CrossRefPubMedGoogle Scholar
  37. 37.
    Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341–53.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–87.CrossRefPubMedGoogle Scholar
  39. 39.
    Nigović B, Mornar A, Sertic M. A review of current trends and advances in analytical methods for determination of statins: chromatography and capillary electrophoresis. In: de Azevedo Calderon L (ed) Chromatogr. Most versatile method Chem. Anal. 2012.
  40. 40.
    Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102–46.CrossRefPubMedGoogle Scholar
  41. 41.
    Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2009;57:243–51.CrossRefGoogle Scholar
  42. 42.
    Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74:818–26.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Egom EE, Rose RA, Neyses L, Soran H, Cleland JGF, Mamas MA. Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. Crit Rev Clin Lab Sci. 2013;50:79–89.CrossRefPubMedGoogle Scholar
  44. 44.
    Likus W, Siemianowicz K, Bieńk K, Pakuła M, Pathak H, Dutta C, Wang Q, Shojaei S, Assaraf YG, Ghavami S, Cieślar-Pobuda A, Łos MJ. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Drug Resist Update. 2016;25:13–25.CrossRefGoogle Scholar
  45. 45.
    Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin N Am. 1994;78:225–45.CrossRefPubMedGoogle Scholar
  46. 46.
    Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586–95.CrossRefPubMedGoogle Scholar
  47. 47.
    Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1:495–505.CrossRefPubMedGoogle Scholar
  49. 49.
    Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O’Grady L, Mercuri M, Mitchel YB. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000;86:221–3.CrossRefPubMedGoogle Scholar
  50. 50.
    Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–60.CrossRefPubMedGoogle Scholar
  51. 51.
    Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997;79:1475–81.CrossRefPubMedGoogle Scholar
  52. 52.
    Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128–33.CrossRefPubMedGoogle Scholar
  53. 53.
    Dart A, Jerums G, Nicholson G, d’Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39–44.CrossRefPubMedGoogle Scholar
  54. 54.
    Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002;137:617–8.CrossRefPubMedGoogle Scholar
  56. 56.
    Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83:687–700.CrossRefPubMedGoogle Scholar
  57. 57.
    Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk. Medicine (Baltimore). 2015;94:e1268.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:S52–60.CrossRefGoogle Scholar
  59. 59.
    Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–80.CrossRefPubMedGoogle Scholar
  60. 60.
    Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679–86.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol. 2011;27:635–62.CrossRefPubMedGoogle Scholar
  62. 62.
    Jose J. Statins and its hepatic effects: newer data, implications, and changing recommendations. J Pharm Bioallied Sci. 2016;8:23.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol. 2006;97:S6–26.CrossRefGoogle Scholar
  64. 64.
    Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, Zhang H. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881–92.CrossRefPubMedGoogle Scholar
  65. 65.
    Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309–14.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367–73.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL. Plasma cholesterol and depressive symptoms in older men. Lancet. 1993;341:75–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Yang C-C, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med. 2003;163:1926.CrossRefPubMedGoogle Scholar
  69. 69.
    McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016. Scholar
  70. 70.
    Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, Olsen JH. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388–94.CrossRefPubMedGoogle Scholar
  72. 72.
    Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121:302–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92.CrossRefPubMedGoogle Scholar
  74. 74.
    Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90:635–7.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. JNCI J Natl Cancer Inst. 2006;98:69–72.CrossRefPubMedGoogle Scholar
  76. 76.
    Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. JNCI J Natl Cancer Inst. 2007;99:32–40.CrossRefPubMedGoogle Scholar
  77. 77.
    Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005;165:2264.CrossRefPubMedGoogle Scholar
  78. 78.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.CrossRefGoogle Scholar
  79. 79.
    Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk. JAMA. 2006;295:74.CrossRefPubMedGoogle Scholar
  80. 80.
    Browning DRL, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–43.CrossRefPubMedGoogle Scholar
  81. 81.
    Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering ldl cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.CrossRefGoogle Scholar
  82. 82.
    Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J, 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention study. N Engl J Med. 2007;357:1477–86.CrossRefPubMedGoogle Scholar
  84. 84.
    Heart Protection Study Collaborative Group HPSC. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013–20.CrossRefGoogle Scholar
  85. 85.
    Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15:269–75.CrossRefPubMedGoogle Scholar
  86. 86.
    Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, Takeuchi H, Mizushige K, Kohno M. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol. 2004;44:904–13.CrossRefPubMedGoogle Scholar
  87. 87.
    Wong V, Stavar L, Szeto L, Uffelman K, Wang CH, Fantus IG, Lewis GF. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis. 2006;184:348–55.CrossRefPubMedGoogle Scholar
  88. 88.
    Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, Shinomiya K, Kosaka H, Kohno M. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J. 2007;71:144–52.CrossRefPubMedGoogle Scholar
  89. 89.
    Mita T, Watada H, Nakayama S, Abe M, Ogihara T, Shimizu T, Uchino H, Hirose T, Kawamori R. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J. 2007;54:441–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Sathyapalan T, Kilpatrick ES, Coady A-M, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94:103–8.CrossRefPubMedGoogle Scholar
  91. 91.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63:2889–934.CrossRefPubMedGoogle Scholar
  92. 92.
    Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J Gen Intern Med. 2015;30:1599–610.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Cai R, Yuan Y, Sun J, Xia W, Huang R, Tian S, Dong X, Shen Y, Wang S. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert Opin Pharmacother. 2016;17:1839–49.CrossRefPubMedGoogle Scholar
  94. 94.
    Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, Chen TJ, Lin SJ, Chiang CE. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60:1231–8.CrossRefPubMedGoogle Scholar
  95. 95.
    Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Rosenson RS. Statins: actions, side effects, and administration—UpToDate. n.d. Accessed 29 Dec 2018.
  97. 97.
    Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13:965–1005.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Kasliwal RR, Bansal M, Gupta R, Shah S, Dani S, Oomman A, Pai V, Prasad GM, Singhvi S, Patel J, Sivam S, Trehan N. ESSENS dyslipidemia: a placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia. Nutrition. 2016;32:767–76.CrossRefPubMedGoogle Scholar
  99. 99.
    Talati R, Sobieraj DM, Makanji SS, Phung OJ, Coleman CI. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc. 2010;110:719–26.CrossRefPubMedGoogle Scholar
  100. 100.
    Cicero AFG, Fogacci F, Rosticci M, Parini A, Giovannini M, Veronesi M, D’Addato S, Borghi C. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutr Metab (Lond). 2017;14:61.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Feuerstein JS, Bjerke WS. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J Diet Suppl. 2012;9:110–5.CrossRefPubMedGoogle Scholar
  102. 102.
    Momtazi AA, Banach M, Pirro M, Katsiki N, Sahebkar A. Regulation of PCSK9 by nutraceuticals. Pharmacol Res. 2017;120:157–69.CrossRefPubMedGoogle Scholar
  103. 103.
    Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8:2076–88.CrossRefPubMedGoogle Scholar
  104. 104.
    Mazzanti G, Moro PA, Raschi E, Da Cas R, Menniti-Ippolito F. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83:894–908.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172–7.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008;49:1595–9.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520–9.CrossRefPubMedGoogle Scholar
  108. 108.
    Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ. A common PCSK9Haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005;45:1611–9.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.CrossRefPubMedGoogle Scholar
  110. 110.
    Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Am Coll Cardiol. 2010;55:2833–42.CrossRefPubMedGoogle Scholar
  111. 111.
    McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344–53.CrossRefPubMedGoogle Scholar
  112. 112.
    Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–900.CrossRefPubMedGoogle Scholar
  113. 113.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408–17.CrossRefPubMedGoogle Scholar
  114. 114.
    Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. JAMA. 2012;308:2497.CrossRefPubMedGoogle Scholar
  115. 115.
    Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS, LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007–17.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995–2006.CrossRefPubMedGoogle Scholar
  117. 117.
    Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M, GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance. J Am Coll Cardiol. 2014;63:2541–8.CrossRefPubMedGoogle Scholar
  118. 118.
    Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H, MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia. J Am Coll Cardiol. 2014;63:2531–40.CrossRefPubMedGoogle Scholar
  119. 119.
    Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R, LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia. JAMA. 2014;311:1870.CrossRefPubMedGoogle Scholar
  120. 120.
    Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331–40.CrossRefPubMedGoogle Scholar
  121. 121.
    Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D’Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of proprotein convertase subtilisin/Kexin Type 9 antibodies in adults with hypercholesterolemia. Ann Intern Med. 2015;163:40.CrossRefPubMedGoogle Scholar
  122. 122.
    Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9.CrossRefPubMedGoogle Scholar
  123. 123.
    Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.CrossRefPubMedGoogle Scholar
  124. 124.
    Peng W, Qiang F, Peng W, Qian Z, Ke Z, Yi L, Jian Z, Chongrong Q. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: a systematic review and meta-analysis. Int J Cardiol. 2016;222:119–29.CrossRefPubMedGoogle Scholar
  125. 125.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigator. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRefPubMedGoogle Scholar
  126. 126.
    Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, Miedema MD, Khalili H, Ahmad Z, Abdullah S, Banerjee S, Brilakis ES. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017. Scholar
  127. 127.
    Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962–71.CrossRefPubMedGoogle Scholar
  128. 128.
    Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.CrossRefPubMedGoogle Scholar
  129. 129.
    Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009–26.CrossRefPubMedGoogle Scholar
  130. 130.
    Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125–34.CrossRefPubMedGoogle Scholar
  131. 131.
    Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67:353–61.CrossRefPubMedGoogle Scholar
  132. 132.
    Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–8.CrossRefPubMedGoogle Scholar
  133. 133.
    ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.CrossRefGoogle Scholar
  134. 134.
    Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. Ann Intern Med. 2014;160:468.CrossRefPubMedGoogle Scholar
  135. 135.
    Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol. 2006;98:34–8.CrossRefGoogle Scholar
  136. 136.
    Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A, Study Investigators. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs. 2009;9:91–101.CrossRefPubMedGoogle Scholar
  137. 137.
    Cicero AFG, Morbini M, Bove M, D’Addato S, Fogacci F, Rosticci M, Borghi C. Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Curr Med Res Opin. 2016;32:1633–8.CrossRefGoogle Scholar
  138. 138.
    Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.CrossRefPubMedGoogle Scholar
  139. 139.
    Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136–50.CrossRefPubMedGoogle Scholar
  140. 140.
    Rader DJ, Brewer HB. Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA. 1993;270:865–9.CrossRefPubMedGoogle Scholar
  141. 141.
    Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999–1001.CrossRefPubMedGoogle Scholar
  142. 142.
    Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993;365:65–9.CrossRefPubMedGoogle Scholar
  143. 143.
    Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010;362:906–16.CrossRefPubMedGoogle Scholar
  144. 144.
    Walton KW, Scott PJ, Dykes PW, Davies JW. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosis. Clin Sci. 1965;29:217–38.PubMedGoogle Scholar
  145. 145.
    Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJP, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo (turnover/cyclohexanedione/plasma exchange/cholestyramine/l-thyroxine), vol. 78. 1981.Google Scholar
  146. 146.
    Ness GC, Pendleton LC, Li YC, Chiang JY. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun. 1990;172:1150–6.CrossRefPubMedGoogle Scholar
  147. 147.
    Gullberg H, Rudling M, Saltó C, Forrest D, Angelin B, Vennström B. Requirement for thyroid hormone receptor β in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol. 2002;16:1767–77.CrossRefPubMedGoogle Scholar
  148. 148.
    Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.CrossRefPubMedGoogle Scholar
  149. 149.
    Duell PB, Santos RD, Kirwan B-A, Witztum JL, Tsimikas S, Kastelein JJP. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. J Clin Lipidol. 2016;10:1011–21.CrossRefPubMedGoogle Scholar
  150. 150.
    Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–40.CrossRefPubMedGoogle Scholar
  151. 151.
    Inclisiran for subjects with ACSVD or ACSVD-risk equivalents and elevated low-density lipoprotein cholesterol. n.d. Accessed 25 Dec 2018.
  152. 152.
    Inclisiran for participants with atherosclerotic cardiovascular disease and elevated low-density lipoprotein cholesterol. n.d. Accessed 25 Dec 2018.
  153. 153.
    Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J. 1983;106:1191–200.CrossRefPubMedGoogle Scholar
  154. 154.
    Glueck C, Gartside P, Fallat R, Sielski J, Steiner P. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemi. J Lab Clin Med. 1976;88:941–57.PubMedGoogle Scholar
  155. 155.
    Rosenson RS, Brewer HB Jr, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256–67.CrossRefPubMedGoogle Scholar
  156. 156.
    Egom EE. Letter from egom regarding article, “High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy”. Circulation. 2014;2014:129.Google Scholar
  157. 157.
    Egom EE. HDL-C/HDL-P ratio. J Am Coll Cardiol. 2015;65:2576.CrossRefPubMedGoogle Scholar
  158. 158.
    Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.CrossRefPubMedGoogle Scholar
  159. 159.
    Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.CrossRefPubMedGoogle Scholar
  160. 160.
    Kastelein JJP, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2015;385:2153–61.CrossRefPubMedGoogle Scholar
  161. 161.
    Nicholls SJ, Ruotolo G, Brewer HB, Wang M-D, Liu L, Willey MB, Deeg MA, Krueger KA, Nissen SE. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2016;10:519–27.CrossRefPubMedGoogle Scholar
  162. 162.
    Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104:984–91.CrossRefPubMedGoogle Scholar
  163. 163.
    Fogacci F, Cicero AFG. Gene targeting for chylomicronemia syndrome: the brave new world. Atherosclerosis. 2018;269:254–5.CrossRefPubMedGoogle Scholar
  164. 164.
    Chaudhry R, Viljoen A, Wierzbicki A. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. Expert Rev Clin Pharmacol. 2018;11:589–98.CrossRefPubMedGoogle Scholar
  165. 165.
    Ikenaga M, Higaki Y, Saku K, Uehara Y. High-density lipoprotein mimetics: a therapeutic tool for atherosclerotic diseases. J Atheroscler Thromb. 2016;23:385–94.CrossRefPubMedGoogle Scholar
  166. 166.
    Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA. 2003;290:2292–300.CrossRefPubMedGoogle Scholar

Copyright information

© Italian Society of Hypertension 2019

Authors and Affiliations

  1. 1.Department of Clinical Medicine, Education Division, School of MedicineTrinity College DublinDublinIreland
  2. 2.Department of CardiologyThe Adelaide and Meath Hospital Dublin, Incorporating the National Children Hospital, Tallaght HospitalDublin 24Ireland
  3. 3.Department of Nutrition, Faculty of Nursing and Professional Health StudiesSlovak Medical UniversityBratislavaSlovakia
  4. 4.Department of General Medicine, Faculty of MedicineSlovak Medical UniversityBratislavaSlovakia
  5. 5.Department of Functional SciencesVictor Babes University of Medicine and PharmacyTimisoaraRomania
  6. 6.1st Department of Internal MedicineComenius University and University HospitalBratislavaSlovakia
  7. 7.Department of Biology, Jessenius Faculty of Medicine in MartinComenius Universityin BratislavaMartinSlovakia
  8. 8.Department of Internal MedicineBrothers of Mercy HospitalBrnoCzech Republic
  9. 9.2nd Department of Surgery, Faculty of MedicineSt. Anne’s University Hospital and Masaryk UniversityBrnoCzech Republic

Personalised recommendations